Quick Facts

• Primary Ophthalmic Use: Temporary relief of eye redness.
• Relieves Symptoms From: Minor eye irritations, such as dust or wind.
• Secondary Use: Management of nasal congestion.

---

Burnil, which contains the active ingredient Tetryzoline (also known as Tetrahydrozoline), is an over-the-counter medication available for specific temporary relief of symptoms. This medication is primarily used to manage ocular redness that may occur due to minor irritations.

It is indicated for temporary relief of eye redness that may result from factors such as dust, smoke, wind, or swimming. The medication may also help relieve discomfort and burning sensations associated with these minor irritations.

In some formulations, Tetryzoline is additionally utilized for the temporary relief of nasal congestion. This application is associated with managing symptoms that involve the nasal and nasopharyngeal mucosa. The approved uses focus on the temporary management of symptoms related to minor, non-serious conditions.

Burnil (Tetryzoline) eligibility is determined by official government labeling, which establishes strict rules for patient use. These rules govern who is permitted to use the medicine and who is prohibited due to specific conditions or age.

Absolute Contraindications

The medicine is contraindicated and must not be used by specific populations. This includes patients with narrow-angle glaucoma and those with a known hypersensitivity to Tetrahydrozoline or any formulation component. Furthermore, Tetryzoline is absolutely contraindicated for children under 2 years of age.

Age and Conditional Use Rules

Usage is permitted for adults and children 6 years of age and older. Use in children under 6 years, however, requires mandatory consultation with a doctor. The product is not recommended for individuals with specific underlying systemic conditions that necessitate pre-consultation, such as high blood pressure, heart disease, diabetes mellitus, or hyperthyroidism, due to the potential for systemic absorption. Additionally, eligibility is conditional for pregnant or breastfeeding individuals, who must ask a health professional before use, as the regulatory data for this group is limited.

Official Regulatory Interaction Profile

The interaction profile for Tetryzoline ophthalmic solution is strictly focused on its effects as a sympathomimetic agent, requiring adherence to regulatory restrictions that prevent additive cardiovascular risk upon systemic absorption.

Category (Regulatory Classification)	Documented Interactions and Restrictions
Formal Contraindication	Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is prohibited due to the risk of severe blood pressure increase (hypertensive crisis) caused by a pharmacodynamic interaction.
Timing Restriction	A mandatory separation period of 14 days is required after discontinuing treatment with MAOIs before Tetryzoline can be administered.
Use with Caution	Co-administration with other sympathomimetic agents is documented as carrying an additive risk of systemic effects, including hypertension or tachycardia. Caution is also necessary with Tricyclic Antidepressants (TCAs) and certain Antihypertensive Agents.

Official labeling for the ophthalmic formulation generally documents a lack of known interaction data concerning major metabolic pathways, such as Cytochrome P450 enzymes, or drug transporters. Furthermore, regulatory information states there are no known interactions with food or non-alcoholic drinks; the interaction status with alcohol is generally listed as unknown. The interaction profile is defined by pharmacodynamic constraints and mandatory procedural restrictions.

Tetryzoline functions as a direct-acting agonist at the alpha-adrenergic receptors, with a relative selectivity for the alpha1-adrenergic subtype. These target receptors are primarily situated on the vascular smooth muscle cells within the local arterioles. The molecular binding event mimics sympathetic nervous system activity, initiating a signaling sequence that compels the vascular smooth muscles into contraction, a process defined as vasoconstriction.

This localized vasoconstriction dramatically narrows the blood vessels at the site of application, altering the local vascular tone. The resulting decrease in the vessel diameter reduces the volume of blood pooled within the superficial tissue, a physiological effect that counteracts vessel engorgement (hyperemia). A constraint intrinsic to this mechanism is the engagement of physiological compensatory feedback. Prolonged, drug-induced vasoconstriction can lead to a sustained dependency on the exogenous agonist, activating regulatory mechanisms that may result in rebound vasodilation upon withdrawal.

Burnil is a medicinal product containing 0.05% Tetryzoline hydrochloride, which is used exclusively via the topical ophthalmic route as an eye drop solution. The official instructions for its use establish a clear, non-continuous application schedule.

The standard labeled regimen for adults and children 6 years of age and over is to administer one to two drops into the affected eye(s) per use. This is intended as an as-needed (intermittent) application, with a strict maximum frequency of up to four times daily. Administration for patients under 6 years of age requires consultation with a healthcare professional, as stated in the product's official labeling.

Usage is subject to mandatory time constraints. Burnil is designated solely for short-term use, and the total treatment duration must not exceed 72 hours (three days). If symptoms persist or worsen beyond this three-day limit, the product must be discontinued, and a medical evaluation is required.

To maintain the product’s integrity and ensure proper delivery, specific conditions must be met prior to and during administration. Contact lenses must be removed before the drops are instilled. Furthermore, users should not proceed if the solution appears to have changed color or become cloudy, and must avoid allowing the container tip to contact any surface. These handling requirements define the necessary procedural context for its official use.

Research evidence / Overview of Studies for Burnil (Tetryzoline)

---

Evidence for Use in Temporary Ocular Redness and Congestion

Research exploring the ophthalmic preparation examined conditions characterized by episodic or acute changes in the eye, such as visible redness and irritation, and applied in studies examining patient-reported experiences. These trials examined outcomes related to physical discomfort and measured the degree of eye redness using standardized clinical scales. The study populations primarily involved adults experiencing minor, non-infectious ocular irritation.

Studies reported measurements indicating changes in the short-term where localized blood vessel appearance changed shortly after topical administration. Studies report that the duration of this observable change in the blood vessels is typically brief, lasting a few hours. This consistent pattern of immediate, short-term localized activity was observed in studies monitoring the compound’s effect, with data showing patterns related to the speed and duration of the localized action.

Research on Duration of Effect and Rebound Phenomena

Pharmacodynamic studies were evaluated in research exploring the effect of this compound, examining outcomes related to the speed and duration of the observed localized changes. Trials also explored the phenomenon of rebound hyperemia, which was observed in some studies to involve increased symptom activity after medication cessation following extended use.

Evidence is limited in precisely defining the chronic use pattern that leads to severe rebound effects, as these long-term phenomena are often documented through clinical case reports rather than large-scale, prospective controlled trials. Furthermore, the existing research does not clearly distinguish between the physiological development of tolerance and tissue reactions stemming from excessive or prolonged application.

Studies in Special Populations and Research Gaps

Research concerning Tetryzoline in specific demographic groups, such as children, was studied for its use, but comparative evidence is lacking for dedicated studies in these groups. The results apply only to the populations studied in the original trials, typically healthy adults.

What is still uncertain about Burnil (Tetryzoline)

Certainty remains low regarding the precise incidence of the rebound effect when the product is used strictly as directed. Comparative evidence is lacking to definitively assess this compound against other topical or systemic decongestant agents in controlled modern trial settings. Finally, the research does not determine whether an individual will respond similarly to the group patterns observed in the studies, highlighting that the findings describe group patterns, not personal outcomes.

Common questions about Burnil (Tetryzoline) (FAQ)

---

Q: How long does it take for Burnil (Tetryzoline) eye drops to start working?

According to the official product information, Burnil (Tetryzoline) is a decongestant. Product information suggests that the effects on blood vessels in the eye may typically begin quickly after application. This action is intended to help relieve minor redness and irritation, but individual response times may vary.

---

Q: Can I use Burnil (Tetryzoline) if I wear contact lenses?

Regulatory documents state that it is generally recommended to remove soft contact lenses before applying Burnil (Tetryzoline). This is to prevent the preservative in the eye drop from being absorbed by the lens. Regulatory labeling advises waiting at least 15 minutes after using the drops before reinserting contact lenses.

---

Q: What should I do if my eye redness does not improve after using Burnil (Tetryzoline)?

Official product information emphasizes that if eye redness or irritation persists or gets worse after using Burnil (Tetryzoline), official information advises discontinuing use of the product if this occurs. This persistent symptom may suggest that the cause of the redness is not simple irritation, and professional assessment is warranted.

---

Q: Is it safe to use Burnil (Tetryzoline) for long periods?

Regulatory information cautions against using Burnil (Tetryzoline) for extended periods. Prolonged or excessive use may lead to a condition called 'rebound congestion,' where the eyes can become more red and irritated when the medication is stopped. The product is generally intended for short-term relief of minor symptoms.

---

Q: How long after opening the bottle should I discard Burnil (Tetryzoline)?

According to the official product information, to help maintain sterility and effectiveness, Burnil (Tetryzoline) eye drops are typically recommended to be discarded within 28 days after the bottle is first opened. It is important to review the product's packaging for any specific manufacturer instructions regarding disposal time.

Storage and Disposal of Tetryzoline Ophthalmic Solution

Official regulatory documents define specific requirements for the storage, handling, and disposal of Tetryzoline ophthalmic solution.

Storage Component	Requirement
Temperature	Store at controlled room temperature, typically 15 C to 30 C (59 F to 86 F). Do not freeze and protect from excessive heat.
Protection	Keep the container tightly closed, away from moisture, and out of reach of children.
Container Rule	Do not touch the applicator tip to any surface to maintain product sterility.
Stability Limit	Do not use if the solution changes color or becomes cloudy. Discard the solution after the labeled in-use period (e.g., 28 days) after first opening.

For disposal, the product must be discarded according to local regulations for pharmaceutical waste. The empty container should have all personal information scratched out before being placed in the trash.